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ABSTRACT
Objective: To examine the independent contributions and combined interactions of medial tempo-
ral lobe atrophy (MTA), cortical and subcortical atrophy, and white matter lesion (WML) volume in
longitudinal cognitive performance.
Methods:A total of 477 subjects with age-relatedWMLwere evaluatedwith brainMRI and annual
neuropsychological examinations in 3-year follow-up. Baseline MRI determinants of cognitive de-
cline were analyzed with linear mixed models controlling for multiple confounders.
Results: MTA and subcortical atrophy predicted significantly steeper rate of decline in global
cognitive measures as well as compound scores for psychomotor speed, executive functions, and
memory after adjusting for age, gender, education, lacunes/infarcts, and WML volume. Cortical
atrophy independently predicted decline in psychomotor speed. WML volume remained signifi-
cantly associated with cognitive decline even after controlling for the atrophy scores. Moreover,
significant synergistic interactions were found between WML and atrophy measures in overall
cognitive performance across time and the rate of cognitive decline. Synergistic effects were also
observed between baseline lacunar infarcts and all atrophy measures on change in psychomotor
speed. Themain results remained robust after exclusion of subjects with clinical stroke or incident
dementia, and after additional adjustments for progression of WML and lacunes.
Conclusions: Brain atrophy and WML are independently related to longitudinal cognitive decline in
small vessel disease.MTA, subcortical, and cortical atrophy seem to potentiate the effect ofWML
and lacunes on cognitive decline. Neurology® 2012;78:1785–1792
GLOSSARY
AD  Alzheimer disease; DSM-IV  Diagnostic and Statistical Manual of Mental Disorders, 4th edition; FLAIR  fluid-
attenuated inversion recovery; LADIS  Leukoaraiosis and Disability; MMSE Mini-Mental State Examination; MPRAGE 
magnetization-prepared rapid gradient echo; MTA  medial temporal lobe atrophy; SVD  small vessel disease;
VADAS  Vascular Dementia Assessment Scale; WML  white matter lesion.
Cerebral small vessel disease (SVD) is the most frequent cause of vascular cognitive impair-
ment.1,2 The imaging hallmarks of SVD are ischemic white matter lesions (WML) and lacunar
infarcts,3,4 which both have been shown to contribute to longitudinal cognitive decline.5–7 At
an individual level, the clinical picture of SVD is variable, and the determinants of poor
cognitive outcome are not completely understood. Beside vascular pathology, concomitant
regional and generalized brain atrophy may have an impact on the clinical outcome.
Brain atrophy, as indicated by smaller gray matter and hippocampal volumes and larger CSF
volumes, correlate with WML volume in subjects without dementia.8 In patients with SVD,
substantial hippocampal neuronal loss has been observed even in the absence of neuropathologic
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evidence of Alzheimer disease (AD).9 Earlier
studies in subjects with cerebrovascular disease
have shown that hippocampal and medial tem-
poral lobe atrophy (MTA) are associated with
cognitive impairment and specifically memory
deficits.10–13 Generalized brain atrophy has been
suggested as a related processes contributing to
cognitive impairment.5,10,11,14,15
Cross-sectional data from the Leukoarai-
osis and Disability (LADIS) study have indi-
cated that a combination of MTA and WML
increases the risk of global cognitive impair-
ment.16 Longitudinal studies focusing on the
consequences of brain atrophy on SVD-
related cognitive decline are still sparse.5,17,18
Particularly, the mediating effects and the in-
teractions between atrophic changes and vas-
cular pathology are largely unknown. The
aims of the present study were to investigate
in a sample of older individuals with age-
related WML 1) whether baseline MTA and
cortical or subcortical atrophy predict baseline
and longitudinal cognitive performance inde-
pendently of coexisting WML and infarcts, 2)
whether these atrophic changes mediate the
effect of WML on cognitive impairment, and
c) whether the different imaging findings have
synergistic effects on cognition.
METHODS Participants. In total, 639 subjects were re-
cruited in the LADIS Study, a prospective longitudinal multi-
center study investigating the role of the age-related WML in
transition to functional disability. A detailed description of the
study has been published elsewhere.19,20 The inclusion criteria
were age 65 to 84 years, changes in cerebral white matter of any
degree according to the revised Fazekas scale (mild/moderate/
severe),19 no or mild impairment in instrumental activities of
daily living, and presence of a contactable informant. The exclu-
sion criteria were presence of severe illness likely leading to drop-
out, severe unrelated neurologic disease, leukoencephalopathy of
nonvascular origin, severe psychiatric disorders, and inability or
refusal to undergo MRI.
All subjects underwent brain MRI and comprehensive neu-
rologic and neuropsychological evaluations at study entry. The
clinical assessments were repeated at yearly intervals at 3 subse-
quent follow-up visits (4 assessments in total), whereas MRI was
replicated at the final visit.
Standard protocol approvals and patient consents. The
local ethics committees of each participating center approved the
study, and all subjects gave written informed consent.
MRI analysis.MRI of the brain was carried out at baseline and
after 3 years according to the same protocol at each study center
comprising the T1-weighted magnetization-prepared rapid gra-
dient echo (MPRAGE), T2-weighted fast spin echo, and fluid-
attenuated inversion recovery (FLAIR) sequences as detailed
before.21,22 The images were analyzed centrally and all ratings
were blinded to clinical information.
Brain atrophy was evaluated by a single rater at baseline on
FLAIR images with a template-based rating scale ranging from
1  no atrophy to 8  severe atrophy separately for cortical
(sulcal) and subcortical (ventricular) regions (figures e-1 and e-2
on theNeurology®Web site at www.neurology.org, respectively).
In case of asymmetry, the side with a more severe atrophy was
used for rating. The sum of cortical and sulcal atrophy score
was taken as a measure of global atrophy. The same template has
been used in previous publications of the LADIS Study.22,23 Reli-
ability analysis revealed 0.90 (weighted Cohen ) intrarater
agreement for both cortical and subcortical atrophy. Inter-rater
agreement was 0.70 for cortical and 0.83 for subcortical atro-
phy.22,23 MTA was rated also by a single rater on the T1-weighted
images resliced in the coronal plane according to the Scheltens
scale ranging from 0 to 4 on the left and right hemispheres.24 The
average of these 2 scores was used in the present study. Intrarater
agreement for MTA was 0.85.16
WML volume was evaluated on the baseline axial FLAIR
images in periventricular, subcortical, and infratentorial regions
using a semiautomated method.21 The lesions were marked and
borders were set by using local thresholding on each slice. Areas
of hyperintensity on T2-weighted images around infarctions and
lacunes were not included. After all lesions were delineated, the
total volume of WML was calculated automatically. At follow-
up, progression of WML was evaluated according to the modi-
fied Rotterdam progression scale (range 0–7).25
The lacunar and nonlacunar infarcts were recorded accord-
ing to their number at baseline and at follow-up. Lacunes were
defined as cavities with a diameter of 3 to 10 mm with signal
intensities similar to CSF in all scan sequences by using a combi-
nation of FLAIR, MPRAGE, and T2 images in order to distin-
guish lacunes from Virchow Robin spaces and microbleeds.25
The nonlacunar infarcts included the larger cortical/lobar in-
farcts related to a blockage of a large cerebral artery.
Of the total sample (n  639), cortical and subcortical atro-
phy ratings were available in 530, MTA 582, WML volume 615,
lacunes 637, and nonlacunar infarcts in 636 subjects. Complete
baseline MRI data for the purposes of the present analysis were
available in 477 subjects. Missing data resulted from insufficient
image quality or incomplete dataset in some cases. The subjects
with complete MRI data did not differ from the other subjects of
the sample in terms of age, gender, or baseline Mini-Mental
State Examination (MMSE) score (p  0.05), but they had
more years of education (10.0 vs 8.4, t  4.5, p  0.001). Of
the 477 subjects, follow-up MRI data were available for 289
subjects. As reported before, the cases with both MRI scans were
younger, had more years of education, higher baseline cognitive
scores, and more often vascular risk factors as compared to those
who only underwent baseline scan.25
Neuropsychological assessment. The neuropsychological
test battery consisted of the MMSE,26 the modified Vascular De-
mentia Assessment Scale– cognitive subscale (VADAS),27 the
Stroop test,28 and the Trail-making test.29 Global cognitive function
was assessed with the total scores of the MMSE and VADAS.
Domain-specific cognitive functions were evaluated with 3
composite scores constructed by averaging the related standard-
ized raw scores.30 Speed and motor control score included the
Trail-making test part A (time), and the maze (time) and digit
cancellation (number of correct responses) subtasks from the
VADAS. Executive functions score was compounded of the sub-
traction scores from the Trail-making (B time A time) and the
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Stroop test (Stroop III time  Stroop II time) as well as the
Symbol Digit Modalities Test (number correct responses) and
verbal fluency (animal names in 1 minute) from the VADAS.
Memory functions score included the VADAS word recall, de-
layed recall, word recognition, and digit span. Low values indi-
cate inferior performance in the MMSE and compound scores,
but the VADAS scale is reversed.
Of the 477 subjects participating in the present study, the base-
line MMSE score was available in 476, VADAS 451, speed 466,
executive functions 437, and memory 471 subjects. Due to death,
dropout, or subject’s inability to complete the entire test battery, the
data were reduced during follow-up. At the final evaluation, neuro-
psychological data were available as follows: MMSE 344, VADAS
313, speed 325, executive functions 299, and memory 325.
Statistical analysis. The MRI predictors of longitudinal cog-
nitive performance were investigated with linear mixed models,
which are able to analyze complex correlation structures and take
all available data into account without assuming equal numbers
of observations at each measurement. The assessment year (base-
line, first, second, and third follow-up year) served as a within-
subject variable. Covariance structure was unstructured. The 5
neuropsychological scores were set as dependent variables sepa-
rately. In all models, age, gender, years of education, as well as
baseline lacunes (0, 1–3, 3) and nonlacunar infarcts (0, 1)
were controlled. The predictor variables included WML volume,
MTA, and global atrophy entered simultaneously. The contribu-
tion of cortical and subcortical atrophy was analyzed separately
by controlling for WML volume and MTA. Logarithmic trans-
formation was applied for WML volume due to substantial pos-
itive skewness. For each dependent variable, we first analyzed the
main effects of the MRI predictors on baseline cognitive perfor-
mance. In the same models, MRI predictor  time interactions
were explored to reveal the influence of atrophic changes on the
rate of cognitive change. Further, the interactions of the different
MRI predictors on overall cognitive performance across time
were analyzed by using centered variables in separate models.
Finally, 3-fold interactions (2 MRI predictors together with
time) were considered to show the combined effects of the MRI
findings on the rate of cognitive decline. The results were ana-
lyzed with PASW Statistics 18.0.2 mixed module.
RESULTS The demographic, clinical, and MRI
characteristics of the subjects are summarized in table
1. The means and intercorrelations of the atrophy
scores and WML volume (mL) are given in table 2.
Baseline cognitive performance. After controlling for
age, gender, education (years), lacunes (no/few/
many), nonlacunar infarcts (no/yes), WML volume,
and global atrophy, the linear mixed models revealed
a significant main effect of MTA on MMSE, VADAS,
speed, executive functions, and memory (F 
10.7–65.8, p  0.01), indicating the independent
association of MTA on baseline cognitive perfor-
mance. Global atrophy was independently associated
with baseline VADAS (F  4.2, p  0.041), speed
(F  8.5, p  0.004), and executive functions (F 
7.8, p  0.005), but not with MMSE or memory
(p  0.05). Specifically, subcortical atrophy was re-
lated to baseline MMSE (F  4.2, p  0.041),
VADAS (F  4.9, p  0.028), speed (F  12.8, p 
0.001), and executive functions (F  7.9, p 
0.005). However, cortical atrophy had no indepen-
dent main effect on any of the baseline cognitive
measures (p  0.05). WML volume remained inde-
pendently associated with all other baseline cognitive
measures (F  5.8–41.3, p  0.05), except the
memory score, even after adjusting for the atrophy
scores and other confounders.
Longitudinal cognitive change. Atrophy score  time
interactions are presented in table 3 (model I), dem-
onstrating the predictive value of these scores on the
rate of cognitive change during follow-up. MTA sig-
nificantly predicted longitudinal decline in all cogni-
tive scores, whereas global atrophy predicted decline
in MMSE, VADAS, speed, and executive functions,
but not in memory. The association of global atro-
phy with cognitive decline was accounted most by
subcortical atrophy, as its interaction with time was
significant for all cognitive variables, but cortical at-
rophy  time interaction was significant only for
speed. Examples of these effects are illustrated in fig-
ure 1, where the subjects are categorized into 2
groups according to the median atrophy scores. After
Table 1 Characteristicsof thesubjects (n477)a
Characteristics Values
Demographics
Age, y, mean (SD) 73.8 (5.0)
Female 259 (54)
Education, y, mean (SD) 10.0 (3.5)
Clinical characteristics
MMSE score, mean (SD) 27.4 (2.4)
Arterial hypertension 320 (67)
Diabetes 67 (14)
History of clinical stroke 134 (28)
Incident clinical stroke 32 (7)
Conversion to dementiab 69 (15)
MRI findings
WML, mild/moderate/
severe
209 (44)/155 (33)/113 (24)
WML progression
score, mean (SD), range
2.0 (1.8), 0–7
Lacunes, no/few/many 261 (55)/155 (33)/61 (13)
Incident lacunes, presentc 48 (17)
Nonlacunar infarcts,
present
45 (9)
Incident nonlacunar
infarcts, presentc
24 (8)
Abbreviations: DSM-IV  Diagnostic and Statistical Man-
ual of Mental Disorders, 4th edition; MMSE  Mini-Mental
State Examination; WMLwhite matter lesions.
a If not otherwise reported, values are number of cases (%).
b Dementia was evaluated at each follow-up visit according
to DSM-IV criteria.
c Follow-up MRI data available for 289 of 477 subjects.
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controlling for MTA, global atrophy, and other con-
founders, WML volume still significantly predicted
longitudinal decline in MMSE (F 8.7, p 0.001),
VADAS (F 5.6, p 0.001), speed (F 21.2, p
0.001), and executive functions (F  11.4, p 
0.001), but not memory (F  1.3, p  0.276).
Interactions of the MRI predictors. Significant syner-
gistic (potentiating) interactions were found between
WML volume and atrophy scores across time in
MMSE and executive functions, and also between
the different atrophy scores in MMSE, executive
functions, and memory (table 3, model II; figure 2).
Table 2 Means and intercorrelations ofWML and brain atrophy in the study sample
Mean (SD) Range
Pearson correlations (p value)
MTA Global atrophy Subcortical Cortical
WML volume, mL 21.4 (22.8) 0.9–156.1 0.37 (0.001) 0.23 (0.001) 0.34 (0.001) 0.02 (0.612)
MTA average 1.0 (0.8) 0–4 0.42 (0.001) 0.47 (0.001) 0.22 (0.001)
Global atrophy 8.0 (2.5) 2–15 0.86 (0.001) 0.80 (0.001)
Subcortical 3.9 (1.6) 1–8 0.38 (0.001)
Cortical 4.1 (1.4) 1–8
Abbreviations: MTAmedial temporal lobe atrophy; WMLwhite matter lesions.
Table 3 Baseline MRI predictors of longitudinal cognitive performance in 3-year follow-upa
MMSE VADAS Speed Executive Memory
Model I
MTA  time 7.3 (0.001)b 4.5 (0.004)b,d 13.3 (0.001)b,c,d 18.4 (0.001)b,c,d 13.2 (0.001)b,c,d
Global atrophy  time 3.6 (0.013)b 3.3 (0.022)b,d 6.1 (0.001)b,c 4.0 (0.008)b NSb
Subcortical  time 6.4 (0.001)b 4.9 (0.002)b,c,d 8.0 (0.001)b,c,d 3.3 (0.019)b 3.1 (0.027)b,d
Cortical  time NS NS 3.2 (0.024) NSc NS
Model II
MTA WML 6.8 (0.009) NS NS 6.1 (0.014) NS
Global atrophy WML NS NS NS 5.4 (0.020) NS
Subcortical WML NS NS NS 4.3 (0.038) NS
Cortical WML NS NSc NS NS NS
Global atrophy MTA NS NS NS 6.0 (0.014)c 4.9 (0.028)b
Subcortical MTA 4.6 (0.033)c NS NS 5.3 (0.022)c,d 5.1 (0.024)b
Cortical MTA NS NS NS NS NS
Model III
MTA WML  time NS NS NS NS NS
Global WML  time 4.1 (0.007)b NS NSb NSd NSd
Subcortical WML  time 4.0 (0.008)b NS NS NS NS
Cortical WML  time NS NS NSb NSc,d NSc,d
Global MTA  time 5.1 (0.002)b,d 2.9 (0.035)b 2.8 (0.039)b,c NS NSb
Subcortical MTA  time 4.3 (0.005)b,d NS NS NSb,c NS
Cortical MTA  time NSd NS NSc NS NS
Abbreviations: DSM-IV  Diagnostic and Statistical Manual of Mental Disorders, 4th edition; MMSE Mini-Mental State
Examination; MTA  medial temporal lobe atrophy; VADAS  Vascular Dementia Assessment Scale–cognitive subscale;
WMLwhite matter lesions.
a Linearmixedmodels (F p value) adjusted for age, gender, education, lacunes, infarcts, and otherMRI co-findings (see text
for details). Cognitive performance was assessed in 4 evaluations at yearly intervals. Model I: independent predictive value
of atrophy scores to the rate of cognitive decline during follow-up. Model II: synergistic interactions between the MRI
findings in overall cognitive performance across time. Model III: synergistic interactions between the MRI findings in the
rate of cognitive decline during follow-up.
b Significant after exclusion of cases with prior or incident clinical stroke.
c Significant after exclusion of cases who converted to dementia (DSM-IV) during follow-up.
d Significant after additional controlling for incident lacunes andWML progression score; data available only for 289 (61%)
subjects.
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Furthermore, 3-fold interactions revealed synergistic
MRI  MRI  time effects on cognitive decline (ta-
ble 3, model III). Significant interactions were also
found between lacunes and all 4 atrophy measures in
decline of speed performance (F  2.3–3.6, p 
0.05).
All significant main effects and interactions were
in the expected direction, i.e., more severe MRI find-
ings predicted inferior/steeper decline of cognitive
performance. Additional controlling for hyperten-
sion had no effect on the longitudinal results. How-
ever, adjusting for incident lacunes (0, 1) and
WML progression as well as exclusion of cases with
clinical stroke or incident dementia (DSM-IV) partly
changed the observed effects (table 3).
DISCUSSION We investigated the individual and
joint effects of baseline regional and global brain at-
rophy on longitudinal cognitive decline among older
individuals with age-related WML. The key finding
of the study was that MTA, subcortical, and cortical
atrophy independently predicted steeper decline of
cognitive performance during the 3-year follow-up.
Cognitive decline was accelerated by the synergistic
interactions between the different atrophy measures
and WML.
Figure 2 Combined effects of white matter lesions (WML) and brain atrophy on executive (A) andmemory (B) performance
Both the main effects and the interactions of WML, medial temporal lobe atrophy (MTA), and subcortical atrophy on cognitive performance were statisti-
cally significant.
Figure 1 Relationship between baseline atrophy scores and the rate of global cognitive decline
Graphs represent model adjusted means with 95% confidence intervals in the Mini-Mental State Examination (MMSE) (A)
and the modified Vascular Dementia Assessment Scale–cognitive subscale (VADAS) (B). Higher values indicate better
performance in MMSE, but worse performance in VADAS. The atrophy scores are categorized into 2 groups according to
the median value: medial temporal lobe atrophy (MTA) low 0–1, high 2–4; subcortical atrophy low 1–4, high 5–8.
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Of the atrophy measures, MTA had the strongest
individual contribution to cognition, as it indepen-
dently predicted both baseline performance and lon-
gitudinal decline in a wide range of cognitive
domains including global cognitive function, psy-
chomotor speed, executive functions, and memory.
The role of MTA in global cognitive decline has been
suggested by earlier studies in cross-sectional1,10,11
and longitudinal31 settings. In subjects with vascular
changes, MTA has been strongly associated with
memory impairment,11–13 but also with deficits in
other domains such as mental speed12 and executive
functions.1,13
Independently of MTA and WML volume,
global brain atrophy was also associated with base-
line performance and the rate of cognitive decline.
This effect was more strongly accounted by subcor-
tical than cortical atrophy. In fact, subcortical atro-
phy significantly predicted change in all cognitive
measures, whereas cortical atrophy was only associ-
ated with decline in psychomotor speed. The results
converge with previous cross-sectional and longitudi-
nal studies suggesting the role of brain atrophy in
SVD-related cognitive impairment.10,11,13,15,18,32,33
However, many of these studies have evaluated only
cortical atrophy or the whole brain volume, and the
differences between cortical and subcortical atrophy
regarding cognitive decline have not been elucidated.
Subcortical atrophy may be of special interest, as it
reflects shrinkage of white matter and the deep gray
matter structures, which are critical for the integrity
of the frontal-subcortical functional networks.34 In a
cross-sectional study of patients with atherosclerotic
disease, larger ventricular volume has been associated
with worse executive and memory performance,
whereas cortical gray matter volume was only related
to executive functions after adjusting for vascular le-
sions.35 Moreover, both subcortical and cortical atro-
phy have been associated with longitudinal decline in
measures of speed and executive functions, but not in
those of memory.5
Some of the previous studies have suggested that
the effect of WML on cognitive decline is overridden
by the stronger influence of brain atrophy.17,33 The
present data do not support this hypothesis, as WML
volume still remained significantly associated with
baseline and longitudinal measures of global cogni-
tive function, speed, and executive functions even af-
ter controlling for MTA, global atrophy, and other
confounders. In our sample, WML correlated signif-
icantly with MTA as well as global and subcortical
atrophy, but not specifically with cortical atrophy.
Previous studies have reported correlations of WML
with both subcortical and cortical atrophy.8,36 Even
though WML and brain atrophy are obviously inter-
related processes, our results suggest that they inde-
pendently and differentially contribute to cognitive
impairment.
Of particular interest is the finding that brain at-
rophy and WML had synergistic interactions in cog-
nitive functioning. WML in combination with either
MTA or subcortical atrophy had potentiating detri-
mental effects on global cognitive function and exec-
utive functions. Moreover, the different types of
atrophic changes—MTA and subcortical atrophy to-
gether—had synergistic interactions in global cogni-
tive function, executive functions, and importantly
also in memory impairment. The synergistic effects
of WML, MTA, and global atrophy were evident
both in overall cognitive performance and in change
over time, suggesting that the influence of the brain
changes in cognitive decline taken together is greater
than the sum of their individual effects.
Synergistic interactions were also observed be-
tween baseline lacunar infarcts and the different atro-
phy measures in longitudinal decline of psychomotor
speed suggesting similar potentiating mechanisms as
between WML and atrophy. Very few studies have
addressed the interaction of brain atrophy with vas-
cular pathology before. Recently, a cross-sectional
study demonstrated that the association of cortical
and subcortical atrophy with executive performance
became stronger with the presence of severe WML,
but no interactions were found in memory perfor-
mance.35 A longitudinal study has reported a cumu-
lative effect of baseline WML and hippocampal
volume on the severity of cognitive decline.37
A limitation of the present study is that we used a
template-based visual rating scale to assess brain atro-
phy instead of volumetric measurements. Visual
scales may not be as sensitive as structural volumetry,
but they are cost-effective, usable in clinical practice,
and have been proved to reach good reliability and
correspondence to volumetric measurements.38,39 In
our evaluations, we separated subcortical and cortical
atrophy, but were not able to evaluate specific corti-
cal regions. Another disadvantage of the study is that
brain atrophy was only evaluated at baseline and
measures of progression were only available for lacu-
nes andWML for a subgroup of the sample. Further-
more, as in any follow-up study of aging and
cognition, a considerable amount of data were lost
during follow-up due to death, subject dropout from
the study, or inability to complete the entire neuro-
psychological evaluation causing a possible bias to-
ward cases with better clinical picture.40 Some
imaging data were also lost because of insufficient
image quality.
Among the strengths of the study are the prospec-
tive longitudinal design and the large sample of sub-
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jects, who at baseline were free from functional
disability and were stratified into all levels of WML.
The comprehensive clinical evaluations included a
detailed neuropsychological assessment carried out at
4 annual visits. Several confounding factors includ-
ing the demographic and clinical variables were con-
trolled. Additional analyses revealed that clinical
stroke played no major role in the observed results,
whereas the effects of atrophy were more prominent
in the subjects who converted to dementia during
follow-up. Progression of lacunes and WML also
modified the effects to some extent, although the
main results remained robust.
In ischemic SVD, brain atrophy and WML are
interrelated processes, which independently contrib-
ute to decline across multiple cognitive domains.
Specifically, brain atrophy amplifies the effects of
WML and lacunes on cognition, exceeding the sum
of the individual effects of these pathologies. The
poorest outcome seems to be determined by a
combination of vascular lesions, MTA, and sub-
cortical atrophy. The results highlight the complex
interplay between vascular and degenerative pa-
thologies leading to progressive cognitive impair-
ment in older individuals with age-related WML.
The pathophysiologic mechanisms of these brain
changes remain unresolved. Atrophy may result
from neurodegenerative processes such as AD, but
it may also derive from cerebral ischemia caused
by the SVD itself. We suggest that in SVD, re-
gional and global atrophic changes deserve equal
attention beside vascular pathology.
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